报告时间：2019年6月13日（星期四）上午8:30-10:30

报告地点：生物楼406会议室

报告人：罗云孜，天津大学

　　报告摘要：

　　Natural products of microbial origin have proven to be the wellspring of clinically useful compounds for human therapeutics. Streptomyces species are predominant sources of bioactive compounds, most of which serve as potential drug candidates. While the exploitation of natural product has been severely reduced over past two decades, the growing crisis of evolution and dissemination of drug resistant pathogens has again attracted great interests in this field. The emerging synthetic biology has been heralded as a new bioengineering platform to discovery novel bioactive compounds and expand bioactive natural product diversity and overproduction. Herein, we analyzed 80 well-annotated Streptomyces genomes and proposed a core genome sequence for chassis design of this species. Meanwhile, several genetic engineering tools were developed for genome editing and natural products exploitation of this genus. By taking advantages of the emerging technique CRISPR/Cpf1, we were able to generate a PAM-free CRISPR genetic editing system working in Streptomyces for efficient DNA knock out and knock in. The CRISPR system developed in this work expanded the synthetic biology toolkit for natural products mining and precise genome engineering in Streptomyces species.

　　报告人简介：

　　罗云孜，女，天津大学教授，博士生导师。2014年在美国伊利诺伊大学香槟分校获得博士学位，师从合成生物学领域专家Huimin Zhao教授。2014年至2015年在美国伊利诺伊大学香槟分校生物基因组研究所从事博士后研究工作。2015年-2019年回国受聘于四川大学生物治疗国家重点实验室，任研究员；2019年加入天津大学化工学院，任教授。现任中国生物工程学会合成生物学专业委员会（筹）委员，中国生物化工青年学者工作委员会委员、中国生物工程协会青年工作委员会委员。主要从事利用合成生物学技术进行天然药物新药开发和重点药物生物合成路径改造等研究工作以及基于合成生物学技术的生物治疗工程技术的开发。至今以第一/通讯作者已在包括Nature Communications、Chemical Society Reviews、Natural Product Reports、ACS Synthetic Biology、Biotechnology and Bioengineering等国际知名期刊杂志发表论文12篇，累计发表论文20篇。

　　联系人：18T6组 周雍进

　　联系电话：0411-84771060